Linagliptin
Linagliptin is used in Diabetes Mellitis for glycemic control as a monotherapy as well as in combination with other antidiabetic drugs Linagliptin is an inhibitor of enzyme DPP-4 (Dipeptidyl peptidase 4) thereby regulating the activation of hormones GLP-1,GLP .Thus regulates glucose hemeostasis
Primary Characteristics
It is classified in Antidiabetic Agent pharmacological group.
Non-proprietary name: Linagliptin.
Pharmacokinetics
None recorded.
Advertisement
Indications
Linagliptin is primarily indicated in conditions like Diabetes mellitus type-ii.
Contraindications
Linagliptin is contraindicated in conditions like Hypersensitivity.
Dosage
Linagliptin's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 5 mg | 5 mg | Every 24h | PO | when we administer this drug with metformin and sulfonylurea the dose of metformin and sulfonylurea should be maintained.no double dose should be taken on the same day |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Linagliptin produces potentially life-threatening effects which include Hypoglycemia , Hypoglycemia. Careful monitoring is needed with proper medical management.
Linagliptin is known to cause more or less tolerable side effects which are usually transient. These include Cough , Hypersensitivity , Hypoglycemia, Nasopharyngitis, Pancreatitis.
Warnings / Precautions
Available Brands
None recorded.